IACH Focus on Leukemia 2020 | The search for better post-MPN AML treatment: decitabine and ruxolitinib
Although post-myeloproliferative neoplasm acute myeloid leukemia (post-MPN AML) is relatively rare, patients with this condition represent a population with an urgent unmet medical need. Farhad Ravandi, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the difficulties finding treatments that are effective for post-MPN AML. With the traditional chemotherapy treatment, patients only survive a few months, especially patents with a history of myelofibrosis. Therefore, there was an effort to combine decitabine and ruxolitinib to hopefully find a more effective treatment. However, the results only indicated a small improvement over decitabine alone. This interview took place during the 2020 Annual Meeting of the International Academy for Clinical Hematology (IACH).
